Abstract
Background: Follicular lymphoma (FL) is an inherently immunosensitive cancer. While PD-1 blockade was associated with a low objective response rate (ORR) in FL, some durable responses were seen. Manipulation of other checkpoint pathways, like 4-1BB, have shown promising activity (Gopal, CCR 2020) and OX40 stimulation may enhance activity of other immunotherapies. We therefore conducted a multi-cohort phase 1b trial testing different combinations of immune checkpoint therapy targeting 4-1BB (utomilumab), OX-40 (PF-04518600), and PD-L1 (avelumab) all in combination with rituximab (R) among patients (pts) with relapsed/refractory (R/R) FL. Methods: Adult pts with R/R grade 1-3a FL who had received ≥ 1 prior therapies (including a CD20 monoclonal antibody) were enrolled. All pts had measurable disease and required therapy based on modified GELF criteria. Pts in need of urgent cytoreductive therapy were excluded. Pts were enrolled onto 2 of 3 planned cohorts (A1 - R, utomilumab, avelumab; A2 - PF-04518600 +/- R, utomilumab). The trial was closed early when development of utomilumab and PF-04518600 was halted by Pfizer. Enrollment ended before dose expansion was completed for cohorts A1 and A2 and before enrollment began for a 3rd cohort (R, avelumab, PF-04518600). Each cohort began with a dose escalation stage (using a standard 3+3 design) followed by a dose expansion stage at the recommended phase 2 dose (RP2D) (15 pts). Treatment consisted of six 28-day cycles for both cohorts (see table for dose levels and dosing details). The co-primary endpoints were RP2D and complete response rate (CRR), assessed using 2014 Lugano criteria. Peripheral blood, stool samples, and tissue biopsies were collected for correlative studies. Results: 24 pts were enrolled at 4 centers, including 1 pt who was initially treated on cohort A2 (with R + PF-04518600), ended treatment due to progression, and then enrolled on cohort A1. In total, 16 pts were treated on cohort A1 and 9 on cohort A2. The median age was 58 (42-76). Pts had received a median of 2 (1-9) prior therapies. 11 pts (46%) had progression within 24 months of initial therapy (POD24). At trial entry, 6 pts (25%) were R-refractory, defined as no response to last R-containing regimen or progression ≤6 months after last R dose. The highest planned dose level (dose level 2) was selected as the RP2D for cohorts A1 and A2. There were no treatment discontinuations due to adverse events (AEs) and no treatment-related deaths. 1 dose-limiting toxicity (grade 3 gastric obstruction, unrelated to study treatment) was observed for a pt in cohort A1. In total, 19/25 (76%) pts had at least 1 treatment-related (tr)AE of any grade, including 7 (28%) pts with grade 3 trAEs. Typical immune-related AEs were not observed. The most common trAEs of any grade were fatigue (24%) and infusion reaction (20%). Grade 3 trAEs included neutropenia in 2 pts (8%), and hypertension, hypertriglyceridemia, hypophosphatemia, lymphopenia, COVID infection, and thromboembolic event in 1 pt each (4%). In cohort A1, the ORR and CRR were 44% and 19%, respectively. Among 10 pts treated at the RP2D, the ORR and CRR were 50% and 30%, respectively. ORRs were observed in 2/5 POD24 pts and 1/4 R-refractory pts in cohort A1. In cohort A2, no responses were observed. After a median follow-up of 16 months, the median progression-free survivals in cohorts A1 and A2 were 7.0 and 3.2 months (m), respectively. The median duration of response in A1 was 9.7m. The 18m overall survivals in cohorts A1 and A2 were 81% and 100%, respectively. We performed 16S ribosomal RNA sequencing of pre- and on-treatment stool samples from pts in cohort A1 and found a positive association between abundance of Akkermansia and ORR to study therapy (p<0.001). Other correlative studies including multiplex immunofluorescence and single-cell analyses (assessing serial biopsy samples) are ongoing. Conclusions: We observed clinical activity with the combination of utomilumab, avelumab, and R, supporting a possible role for 4-1BB agonist therapy in FL. In contrast, our limited results do not support a role for OX40 targeting in this disease. Correlatives studies are ongoing which may shed further light on predictors of response. Interestingly, we found an association between Akkermansia and response, which has been reported in checkpoint blockade studies in solid tumors and supports the hypothesis that the microbiome impacts response to immunotherapies in lymphomas. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.